Cameroon
Tuberculosis profile
| High HIV burden |
Population  2013 22 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 7.8 (4.9–9.9) 35 (22–45)
Mortality (HIV+TB only) 7.9 (6–10) 35 (27–45)
Prevalence  (includes HIV+TB) 66 (37–110) 299 (164–472)
Incidence  (includes HIV+TB) 52 (47–59) 235 (210–265)
Incidence (HIV+TB only) 19 (18–23) 87 (81–104)
Case detection, all forms (%) 49 (44–55)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.6 (0.01–5.5) 13 (0.2–28)
MDR-TB cases among notified pulmonary
TB cases
540 (2–1 100) 210 (3–460)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 15 103   1 147
Pulmonary, clinically diagnosed 5 514   0
Extrapulmonary 3 884   0
       
Total new and relapse 25 648    
Previously treated, excluding relapses 515    
Total cases notified 26 163    
Among 24 501 new cases:
291 (1%) cases aged under 15 years; male:female ratio: 1.5
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 (<1%) 721 (43%) 721
Laboratory-confirmed RR-/MDR-TB cases     123
Patients started on MDR-TB treatment     200
TB/HIV 2013 Number (%)
TB patients with known HIV status 21 371 (82)
HIV-positive TB patients 8 161 (38)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 7 392 (91)
HIV-positive TB patients on antiretroviral therapy (ART) 5 254 (64)
HIV-positive people screened for TB 21 329  
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 79
Previously treated cases registered in 2012 65
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 13
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 3
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 4.9
% Funded domestically 28%
% Funded internationally 72%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-08 Data: www.who.int/tb/data